Sentences with phrase «derived oligodendrocyte»
Human Embryonic Stem Cell - Derived Oligodendrocyte Progenitor Cell Transplants Improve Recovery After Cervical Spinal Cord Injury.
http://asteriasbiotherapeutics.com/
Immunological properties of human embryonic stem cell - derived oligodendrocyte progenitor cells.
Preclinical Safety of Human Embryonic Stem Cell - Derived Oligodendrocyte Progenitors Supporting Clinical Trials In Spinal Cord Injury.
At the International Society for Stem Cell Research 2017 Annual Meeting (June 14 - 17, 2017; Boston, USA), Asterias Biotherapeutics, Inc (CA, USA) will present new 9 - month efficacy and safety data from their ongoing SCiStar Phase I / IIa trial of human embryonic stem cell - derived oligodendrocyte progenitor cells.
If you are attending ISSCR 2017, you can attend the Asterias workshop, titled «Clinical Development of hESC - derived Oligodendrocyte Progenitors for the Treatment of Spinal Cord injury» on June 13, 2017 at 10:45 am.
Ten people will receive injections into the injury site of hESC - derived oligodendrocyte progenitor cells, which stimulate the growth of new and severed nerves and recoat damaged nerves with myelin.
Geron Corp., which earlier got permission to administer stem cell — derived oligodendrocyte progenitors to treat spinal injury, has been bogged down in delays and may not begin its trial until late next year.
\ n \ nMeanwhile, work in the private sector in collaboration with academic institutions, has produced an IND that is now before the FDA, for a human trial with hESC - derived oligodendrocytes to remyelinate damaged spinal chord axons.
Not exact matches
Most of these trials involve stem cell - derived neural progenitor cells, which can turn into several different types of brain or spinal cord cells, or oligodendrocyte progenitor cells, which create the myelin sheaths that insulate and protect nerve cells.
Previous research in rodent disease models has shown that transplanted oligodendrocyte precursor cells derived from embryonic stem cells and from human fetal brain tissue can successfully create myelin sheaths around nerve cells, sometimes leading to dramatic improvements in symptoms.
Most of these trials involve stem cell — derived neural progenitor cells, which can turn into several different types of brain or spinal cord cells, or oligodendrocyte progenitor cells, which create the myelin sheaths that insulate and protect nerve cells.
AST - OPC1, an oligodendrocyte progenitor cell population derived from human embryonic stem cells, has been shown in preclinical testing in animals and in vitro to have three potentially reparative functions that address the complex pathologies observed in demyelination disorders, such as spinal cord injuries, and multiple neurodegenerative diseases, including multiple sclerosis and white matter stroke.